Biogen | BIIB - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
AbbVie USD 3.84B 205M 2026-09
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
Bayer EUR 3.96B 267M 2026-06
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 364.27M 12.54M 2026-09
Merck USD 2.86B 25M 2026-09
Moderna USD 216M 43M 2026-06
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novartis USD 3.08B 163M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.31B 325M 2026-09
Sanofi EUR 2.63B 140M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Teva Pharmaceutical Industries USD 1.03B 34M 2026-06
Ultragenyx Pharmaceutical USD 88M 0 2026-06
United Therapeutics USD 206.7M 50.1M 2026-06
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09